Europe Gene Synthesis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Europe Gene Synthesis Market Overview

The Europe gene synthesis market was valued at USD 1.00 billion in 2025 and is projected to reach USD 4.62 billion by 2033, growing at a CAGR of 21.10% from 2026 to 2033. The market is witnessing steady expansion driven by increasing demand for precision medicine, rapid advancements in synthetic biology, and growing applications in pharmaceuticals, biotechnology research, and genetic engineering.

Rising investment in genomics research, coupled with strong government and EU-level funding initiatives for life sciences innovation, is significantly accelerating market growth across the region. In addition, the expanding use of gene synthesis in drug discovery, vaccine development, and agricultural biotechnology is further strengthening adoption. The presence of leading biotech firms and advanced research infrastructure across countries such as Germany, the U.K., France, and Switzerland is also contributing to the growing integration of automated and high-throughput gene synthesis technologies.

Key Market Trends & Insights

• Germany dominated the Europe gene synthesis market with the largest revenue share of 28.6% in 2025, supported by strong biotechnology industry, advanced genomic research infrastructure, and extensive presence of pharmaceutical and life sciences companies.
• The Consumables segment led the market with a 44.8% share in 2025, driven by continuous and recurring demand for oligonucleotides, reagents, enzymes, and kits required in every synthesis workflow.
• United Kingdom is expected to be the fastest-growing region at a CAGR of 9.1% from 2026 to 2033, fueled by strong investments in genomics programs, expanding biotech startups, and government-backed initiatives in precision medicine and advanced therapeutics.
• Software & Services are the fastest-growing component type, projected to register a CAGR of 11.3%, reflecting the surge in adoption of AI-based gene design platforms and cloud-integrated bioinformatics tools.
• The Standard Gene segment dominated the gene type category with a 47.2% revenue share in 2025, led by widespread use in basic research, cloning, and routine molecular biology applications.
• Synthetic Biology accounted for 34.9% of the market, preferred by extensive use of engineered DNA constructs in designing biological systems and metabolic pathways.
• The Vaccine Design segment is the fastest-growing application category, with a CAGR of 11.5%, driven by increasing focus on mRNA vaccines, DNA-based immunotherapies, and rapid response platforms for infectious diseases.

Market Size & Forecast

• Global Market Value (2025): USD 1.00 Billion
• Expected Market Value (2033): USD 4.62 Billion
• Forecast CAGR (2026–2033): 21.10%
• Leading Country in 2025: Germany
• Fastest Growing Country: United Kingdom

Report Scope and Europe Gene Synthesis Market Segmentation

Europe Gene Synthesis Market Trends

Trend: Expansion of AI-Driven & High-Throughput Gene Design Platforms

Pharmaceutical companies and biotech firms across Europe are increasingly adopting automated, high-throughput gene synthesis platforms to accelerate DNA construct design, improve accuracy, and reduce turnaround time for complex genetic sequences. Integration of AI-based sequence optimization and bioinformatics tools is enhancing predictive design capabilities and enabling large-scale synthetic biology projects. Academic institutes and research organizations are also leveraging cloud-based gene synthesis platforms to support collaborative genomics research and precision medicine development, while advanced automation ensures scalability and reproducibility across experimental workflows. For instance, companies are deploying AI-assisted gene assembly systems to optimize codon usage and reduce synthesis errors in large-scale genomic studies.

Europe Gene Synthesis Market Dynamics

Key Market Driver: Rising Demand for Precision Medicine & Biopharmaceutical Innovation

The rapid expansion of precision medicine and biologics development across Europe is driving strong demand for synthetic DNA and gene constructs used in drug discovery, vaccine development, and therapeutic protein engineering. Pharmaceutical companies, research institutes, and contract development organizations are increasingly integrating gene synthesis into early-stage R&D pipelines to accelerate target identification and reduce development timelines. Growing government funding for genomics initiatives and strong EU-level support for life sciences innovation are further strengthening market adoption. For instance, gene synthesis is widely used in developing mRNA-based vaccines and engineered cell therapies for targeted disease treatment.

Key Restraint/Challenge: High Initial Investment Cost of Advanced Simulators

A major restraint in the Europe gene synthesis market is the high capital investment required for advanced synthesis platforms, including automated DNA assembly systems, sequencing validation tools, and AI-enabled design software. The cost of establishing and maintaining high-throughput synthesis laboratories, along with recurring expenses for reagents, software licenses, and skilled workforce, limits adoption among small and mid-sized research institutions. In addition, strict regulatory compliance and quality assurance requirements increase operational complexity and overall expenditure. For instance, smaller biotech startups often face financial barriers in deploying fully automated gene synthesis pipelines for large-scale research projects.

Key Market Opportunity: Integration of Cloud-Based Genomics & AI-Powered Design Ecosystems

The integration of cloud computing and artificial intelligence into gene synthesis workflows presents a significant growth opportunity across Europe, enabling faster sequence design, real-time collaboration, and scalable data-driven research. Cloud-based platforms allow researchers to share genomic data securely and perform distributed gene assembly simulations, improving efficiency and innovation in synthetic biology. AI-powered tools further enhance error correction, sequence prediction, and functional gene optimization, expanding applications in therapeutics and industrial biotechnology. For instance, cloud-enabled gene design platforms are being used to support multi-institutional collaborations in synthetic vaccine development and genome engineering projects.

Europe Gene Synthesis Market Scope

The Europe gene synthesis market is segmented on the basis of component, gene type, synthesis type, application, method, end user, and distribution channel.

• By Component

On the basis of component, the Europe gene synthesis market is segmented into synthesizers, consumables, and software & services. The Consumables segment dominated the market with a 44.8% share in 2025, driven by continuous and recurring demand for oligonucleotides, reagents, enzymes, and kits required in every synthesis workflow. These materials are essential for both standard and custom gene construction, making them indispensable across academic and commercial laboratories. High consumption frequency in large-scale sequencing and drug discovery programs further strengthens this segment’s dominance. Continuous advancements in high-fidelity reagents are improving accuracy and reducing synthesis errors. Expanding use of gene synthesis in vaccine and biologics development is also increasing consumables demand. The segment benefits from strong repeat purchase cycles across biotech and pharma industries.

The Software & Services segment is the fastest-growing with a CAGR of 11.3% (2026–2033), driven by increasing adoption of AI-based gene design platforms and cloud-integrated bioinformatics tools. These solutions enable rapid sequence optimization, error correction, and predictive modeling for complex gene constructs. Rising demand for automated workflow management in synthetic biology is further boosting adoption. Integration of machine learning algorithms is improving design accuracy and reducing development time. Pharmaceutical companies are increasingly relying on outsourced gene design and analytical services to reduce operational burden. Expanding digital transformation across life sciences is accelerating growth of this segment.

• By Gene Type

On the basis of gene type, the market is segmented into standard gene, express gene, complex gene, and others. The Standard Gene segment dominated the market with a 47.2% share in 2025, due to its widespread use in basic research, cloning, and routine molecular biology applications. These genes are relatively simpler to synthesize, enabling faster turnaround times and lower production costs. Academic institutes and research laboratories extensively use standard genes for experimental validation and educational purposes. High reproducibility and well-established protocols further support their dominance. Increasing use in early-stage drug discovery also strengthens demand. The segment benefits from broad applicability across nearly all life sciences disciplines.

The Complex Gene segment is the fastest-growing with a CAGR of 10.7% (2026–2033), driven by rising demand for multi-domain constructs, long DNA sequences, and engineered genetic systems. These genes are increasingly required in synthetic biology, advanced therapeutics, and industrial biotechnology. Growing focus on cell and gene therapy development is significantly boosting demand. Technological advancements in error-free assembly and high-fidelity synthesis are enabling production of longer and more complex sequences. Pharmaceutical companies are increasingly using complex genes for next-generation biologics and protein engineering. Expansion of precision medicine research is further accelerating growth in this segment.

• By Gene Synthesis Type

On the basis of gene synthesis type, the market is segmented into gene library synthesis and custom gene synthesis. The Custom Gene Synthesis segment dominated the market with a 55.6% share in 2025, driven by rising demand for tailor-made DNA sequences for drug discovery, vaccine development, and synthetic biology applications. Pharmaceutical and biotechnology companies heavily rely on custom synthesis for targeted research and functional studies. Increasing complexity of genetic engineering projects is further boosting demand. High accuracy, flexibility, and rapid turnaround time make this segment highly preferred. Expanding use in antibody engineering and therapeutic research supports its dominance. The segment benefits from strong outsourcing trends in biotech R&D.

The Gene Library Synthesis segment is the fastest-growing with a CAGR of 10.2% (2026–2033), driven by increasing use in high-throughput screening and large-scale functional genomics studies. These libraries enable researchers to analyze thousands of gene variants simultaneously, accelerating discovery processes. Rising demand for CRISPR-based screening and synthetic biology applications is fueling adoption. Pharmaceutical companies are using gene libraries for target identification and drug validation. Advancements in automation and sequencing technologies are improving library construction efficiency. Expanding application in personalized medicine and genetic research is further supporting growth.

• By Application

On the basis of application, the market is segmented into synthetic biology, genetic engineering, vaccine design, therapeutic antibodies, and others. The Synthetic Biology segment dominated the market with a 34.9% share in 2025, driven by extensive use of engineered DNA constructs in designing biological systems and metabolic pathways. Pharmaceutical and industrial biotech companies are heavily investing in synthetic biology for drug development and bio-based production. Rising demand for sustainable biomanufacturing is further supporting adoption. Gene synthesis plays a critical role in constructing artificial genetic circuits and engineered organisms. Continuous innovation in genome editing technologies is strengthening this segment’s leadership. Expanding research funding in Europe is also driving growth.

The Vaccine Design segment is the fastest-growing with a CAGR of 11.5% (2026–2033), driven by increasing focus on mRNA vaccines, DNA-based immunotherapies, and rapid response platforms for infectious diseases. Gene synthesis enables fast development of antigen sequences and vaccine candidates. Pharmaceutical companies are investing heavily in platform-based vaccine technologies. Growing preparedness for future pandemics is accelerating demand. Advancements in synthetic gene assembly are reducing vaccine development timelines. Expanding public health funding across Europe is further boosting this segment.

• By Method

On the basis of method, the market is segmented into solid phase synthesis, chip-based DNA synthesis, and PCR-based enzyme synthesis. The Solid Phase Synthesis segment dominated the market with a 49.3% share in 2025, due to its high reliability, precision, and widespread adoption in oligonucleotide production. This method is extensively used in both research and commercial gene synthesis workflows. It offers strong scalability and consistent sequence accuracy. Pharmaceutical companies prefer this method for standardized gene construction. Established infrastructure and mature technology further support its dominance. Continuous optimization of chemical synthesis processes enhances efficiency and yield.

The Chip-Based DNA Synthesis segment is the fastest-growing with a CAGR of 11.0% (2026–2033), driven by demand for ultra-high-throughput and miniaturized gene synthesis platforms. This technology enables parallel synthesis of thousands of DNA sequences simultaneously. Rising adoption in synthetic biology and large-scale screening is boosting growth. Lower reagent consumption and reduced costs per sequence further enhance attractiveness. Integration with AI-driven design platforms is improving efficiency and accuracy. Expanding use in genome-scale engineering projects is accelerating adoption.

• By End User

On the basis of end user, the market is segmented into academic & research institutes, diagnostics laboratories, biotech & pharmaceutical companies, and others. The Biotech & Pharmaceutical Companies segment dominated the market with a 58.1% share in 2025, driven by extensive use of gene synthesis in drug discovery, biologics development, and clinical research. These organizations have high R&D budgets and strong adoption of advanced genomic technologies. Increasing focus on precision medicine and targeted therapies is further boosting demand. Outsourcing of gene synthesis services is also widely practiced to improve efficiency. Strong regulatory compliance capabilities make this segment highly influential. Continuous innovation in biologics and cell therapies supports dominance.

The Academic & Research Institutes segment is the fastest-growing with a CAGR of 9.8% (2026–2033), driven by increasing government funding for genomics and synthetic biology research. Universities and public research organizations are expanding their use of gene synthesis for fundamental and applied studies. Growing collaboration with biotech firms is accelerating technology adoption. Declining costs of synthesis technologies are making access easier. Expansion of genomic education programs is further supporting demand. Rising focus on translational research is strengthening growth.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, online distribution, and third-party distribution. The Direct Tender segment dominated the market with a 62.4% share in 2025, driven by large procurement contracts from pharmaceutical companies, research institutes, and government-funded projects. This channel ensures reliability, regulatory compliance, and bulk purchasing advantages. Long-term partnerships between suppliers and end users strengthen dominance. High-value contracts for customized gene synthesis further support this segment. Preference for secure and traceable procurement processes enhances adoption. Strong institutional demand continues to sustain growth.

The Online Distribution segment is the fastest-growing with a CAGR of 12.1% (2026–2033), driven by increasing digitization of life sciences procurement and adoption of e-commerce-style biotech platforms. Researchers are increasingly ordering gene constructs through online portals for faster turnaround and convenience. Integration of AI-based design and ordering systems is streamlining workflows. Small and mid-sized laboratories are particularly driving this shift. Expansion of cloud-based biotech marketplaces is further accelerating growth. Improved logistics and delivery systems are enhancing reliability and adoption.

Europe Gene Synthesis Market Regional Analysis

Germany dominated the Europe gene synthesis market with the largest revenue share of 28.6% in 2025, supported by strong biotechnology industry, advanced genomic research infrastructure, and extensive presence of pharmaceutical and life sciences companies. The country also benefits from significant government funding in genomics and synthetic biology, high adoption of automated gene synthesis platforms, and strong collaboration between academic institutions and industry players. Increasing focus on precision medicine, biologics development, and industrial biotechnology continues to strengthen Germany’s leadership position in the European gene synthesis market.

The Germany Gene Synthesis Market Insight

The Germany gene synthesis market remains the largest contributor in Europe, driven by its strong pharmaceutical manufacturing base, advanced biotechnology infrastructure, and extensive academic research ecosystem. High adoption of automated gene synthesis platforms and AI-based bioinformatics tools is supporting large-scale genomic research and drug discovery activities. Government funding for life sciences innovation and strong collaboration between industry and research institutes are further accelerating market growth. In addition, increasing focus on biologics, cell and gene therapy, and synthetic biology is strengthening Germany’s leadership position in the European market.

United Kingdom Gene Synthesis Market Insight

The United Kingdom gene synthesis market is witnessing strong growth due to expanding genomics research programs, rising biotechnology startup activity, and strong government support for precision medicine initiatives. The country’s well-established academic institutions and biotech clusters are driving demand for custom gene synthesis in therapeutic development and vaccine research. Increasing integration of AI-driven gene design platforms is improving research efficiency and accuracy. In addition, strong collaboration between universities, pharmaceutical companies, and research organizations is accelerating innovation across synthetic biology applications.

France Gene Synthesis Market Insight

The France gene synthesis market is growing steadily, supported by strong academic research infrastructure, government-backed biotechnology programs, and increasing adoption of synthetic biology tools. Pharmaceutical and life sciences companies are increasingly utilizing gene synthesis for drug discovery, vaccine development, and molecular diagnostics. Rising investment in genomics research and expanding collaborations between public and private sectors are strengthening market development. In addition, growing focus on personalized medicine and biologics production is further supporting market expansion in France.

Spain Gene Synthesis Market Insight

The Spain gene synthesis market is growing steadily, driven by expanding biomedical research infrastructure, increasing pharmaceutical R&D investments, and rising focus on genetic engineering applications. Academic and research institutions are increasingly adopting gene synthesis for molecular biology studies and therapeutic research. Growing participation in EU-funded genomics programs is further supporting market expansion. In addition, rising demand for personalized medicine and biotechnology-based healthcare solutions is accelerating adoption across the country.

Europe Gene Synthesis Market Share

The Europe Gene Synthesis industry is primarily led by well-established companies, including:

• Twist Bioscience (U.S.)
• Integrated DNA Technologies (U.S.)
• Thermo Fisher Scientific, Inc. (U.S.)
• Ginkgo Bioworks (U.S.)
• Synthego (U.S.)
• ATUM (U.S.)
• Codex DNA (U.S.)
• Azenta Life Sciences (U.S.)
• OriGene Technologies (U.S.)
• Synbio Technologies (U.S.)
• Eton Bioscience (U.S.)
• Blue Heron Biotechnology (U.S.)
• GenScript Biotech Corporation (China)
• Bio Basic Inc. (Canada)
• Biomatik Corporation (Canada)
• Eurofins Genomics (Luxembourg)
• Creative Biogene (U.S.)
• Plasmidsaurus (U.S.)
• DNA Script (France)
• Benchling (U.S.)

Latest Developments in Europe Gene Synthesis Market

• In January 2025, DNA Script announced a breakthrough in enzymatic DNA synthesis, enabling the production of longer and more complex DNA sequences with improved accuracy, which is expected to significantly advance applications in mRNA vaccines, antibody engineering, and gene therapy development across Europe
• In May 2023, the company launched the SYNTAX STX-200 platform, a next-generation automated DNA synthesis system designed for higher throughput and improved scalability, supporting rapid DNA construction for pharmaceutical R&D and genome engineering applications
• In April 2022, DNA Script introduced an Early Access Program for its SYNTAX system, enabling selected European research institutions and biofoundries to access enhanced gene synthesis capabilities, thereby improving prototyping speed and expanding applications in synthetic biology research
• In November 2021, the company received CE Mark approval for the SYNTAX platform, allowing commercialization across Europe and strengthening regulatory acceptance of enzymatic DNA synthesis technology for use in academic, pharmaceutical, and biotechnology laboratories.
• In June 2021, DNA Script (France) launched its SYNTAX System, the world’s first benchtop enzymatic DNA synthesis platform, enabling on-demand production of synthetic DNA directly in laboratories and reducing reliance on external suppliers, which significantly accelerated workflows in genomics and synthetic biology applications

SKU-62810